The effect of Acanthopanax sessiliflorus using the model of neuropathic pain and formalin-induced pain.

(1)

緖論

,

1)

,

2007 8 30 2007 9 2

2007 9 14

: , 907-8

(Tel : 054-281-0055, Fax : 054-281-7463, E-mail: beautysuny@hanmail.net)

五加皮

김장현

¹

, 장규태

²

, 강미선

³

The effect of Acanthopanax sessiliflorus using the model of neuropathic pain and formalin-induced pain.

Jang-hyun Kim

¹

, Gyu-tae Chang

²

, Mi-sun Kang

³

1

Department of Pediatrics, College of Oriental Medicine, Dongguk University

2

Department of Pediatrics, College of Oriental Medicine, Kyunghee University

3

Department of Pediatrics, Daeguhaany University, Pohang Oriental Hospital

Objectives : This study was conducted to determine the analgesic effect of Acanthopanax sessiliflorus using the model of neuropathic pain and formalin-induced pain.

Methods : A model of neuropathic pain was made by injuring the tibial nerve and sural nerve while the common peroneal nerve was maintained. After 2 weeks, the Acanthopanax sessiliflorus was orally administered to rats. The author performed behavioral teststo try out mechanical allodynia using von frey filament and cold allodynia using acetone, which are calculated by counting withdrawal response on foot. Thirty minutes after the Acanthopanax sessiliflorus injection in the abdominal cavity, the formalin test was performed. 2% formalin in a volume of 20 was injected subcutaneously into the plantar surface of the hindpaw with 26-G needle. To access formalin-induced pain behavior, paw licking time was measured every 5 min.

Results : The Acanthopanax sessiliflorus 400mg/10ml/kg group showed significant decrease the withdrawal response of mechanical allodynia using von frey filament in the 10min, 30min, 60min and 120min increments compared with the control group. There were no significant differences in each group in the withdrawal response of cold allodynia using acetone. The Acanthopanax sessiliflorus group showed significant decrease in the formalin-induced pain behavior in the 15min, 20min and 25min increments compared with the control group.

Conclusions : The Acanthopanax sessiliflorus may have a significant analgesic effect on the general pain as well as nerve injury pain.

Key Words : Acanthopanax sessiliflorus , neuropathic pain, formalin-induced pain

(2)

2)

.

,

3)

.

, , , , , , ,

, ,

4)

.

, ,

Reynold PAG(periaqueductal gray)

,

5)

.

,

.

3)

, ,

6)

.

5,7-14)

.

15)

,

, (+)-Syringaresinol-di-

O-β-d-glucoside (SR) AP-1 ( ) NF-κB

16)

, carr- ageenan- Freund's complete adjuvant (FCA)

chiisanoside chiisanogenin

17)

.

實驗材料 및 方法

1.

신경병리성 통증 모델

1)

175±25g Sprague Dawley

( , ) .

halothane

povidone iodine isopropyl

alcohol .

microforcep

, ,

6.0 . kanamycin

(Fig. 1-2).

2)

6 ,

(control),

50mg/10ml/kg , 100mg/10ml/kg , 200mg/

(3)

10ml/ kg , 400mg/10ml/kg .

pretest ,

2 .

3)

(Acanthopanax sessiliflorus, ,

) 300g , 80%

3 ,

(-66 ,

10mmHg) .

9.69% .

50mg/10ml/kg, 100mg/10ml/kg, 200mg/10ml/kg, 400mg/10ml/kg

. 4)

2 .

.

10 , 30 , 60 , 120

10 ,

10 , 60 , 120 10

. 5)

± (Mean±S.E.)

,

Window SPSS 10.0 .

repeated ANOVA test

, LSD .

P<0.05 .

2.

포르말린 테스트 통증 모델

1)

30±5g ICR ( , )

8 . 4

, 2

.

2)

(4)

(control) 100mg/10ml/kg

. 3)

,

100mg/10ml/kg 30

.

4)

12×30×13cm .

45 camcorder

(JVC S-VHS) (Fig. 3-5).

5)

26-gauge needle

2% 20

.

off-line ,

TV

5 .

6)

± (Mean±S.E.)

,

Window SPSS 10.0 .

Kruskal-Wallis One Way

ANOVA on Ranks ,

(5)

Dunnett's test . P<0.05 .

實驗成績

1.

신경병리성 통증 모델

1)

10 , 30 , 60 , 120 88±5.4%,

100±0%, 94±2.7%, 80±8.9%

400mg/10ml/ 52±10.0%, 42±10.6%,

56±8.2%, 48±8.8% 400mg/10ml/

(p<0.05) (Table 1, Fig. 6).

2)

Group Min Neuropathic Pain(VF(%))

Pretest 10 30 60 120

Control 100±0 88±5.4 100±0 94±2.7 80±8.9

50mg 100±0 100±0 100±0 100±0 100±0

100mg 100±0 100±0 100±0 96±1.1 96±1.1

200mg 100±0 92±2.2 100±0 76±6.6 76±6.6

400mg 86±3.0 52±10.0* 42±10.6* 56±8.2* 48±8.8*

Asterisks (*) indicates significant differences compared to saline injected control group (p<0.05). The number of each group is 6.

All values are Mean±S.E.

Response Rate(%)

100

80

60

40

20

0

Pretest 10 30 60 120

Time (min)

Control 50mg 100mg 200mg 400mg

(6)

(p>0.05) (Table 2, Fig. 7).

2.

포르말린 테스트 통증 모델

5 , 10

78.9±9.6 , 11.6±4.8 , 100mg/10ml/kg

75.7±11.2 , 18.3±18.2

(p>0.05) , 15 , 20 , 25

25.5±8.0 , 41.8±15.3 , 54.2

±13.1 , 15.8

±11.9 , 15.3±0.4 , 37.6±8.4

(p<0.05) (Table 3, Fig. 8).

考察

, ,

Group Min Neuropathic pain(acetone(%))

Pretest 10 60 120

Control 84±1.5 90±1.7 88±1.8 94±0.9

50mg 96±1.5 92±1.4 86±2.5 86±2.2

100mg 98±0.7 92±0.7 96±0.9 80±3.1

200mg 92±2.6 82±4.3 72±7.4 88±4.3

400mg 88±1.8 80±5.7 72±3.4 74±4.0

There were no significant differences each group on cold allodynia. The number of each group is 6.

All values are Mean±S.E.

120

100

80

60

40

20

0

Pretest 10 60 120

Time (min)

Control 50mg 100mg 200mg 400mg

Response Rate(%)

(7)

.

,

18,19)

. 1994 IASP (International Association of Study of Pain) Task-Force team

.

, NSAIDs

( ), opioids( )

. 1

,

20,21)

.

, ,

,

, , Farby

22)

. , ,

,

Group Min

Formalin test(sec)

0 5 10 15 20 25 30 35 40

control 0 78.9±9.6 11.6±4.8 25.5±8.0 41.8±15.3 54.2±13.1 33.4±14.0 33.0±11.8 14.4±13.4 Acanthopanax 0 75.7±11.2 18.3±18.2 15.8±11.9* 15.3±0.4* 37.6±8.4* 33.4±4.1 32.6±7.2 14.8±18.6 Time spent in pain behavior of experimental animals treated with saline and acanthopanax in each 5-min. Asterisks (*) indicates significant differences compared to saline injected control group (p<0.05). The number of each group is 8.

All values are Mean±S.E.

Response Time(seo)

80

70

60

50

40

30

20

10

0

0 5 10 15 20 25 30 35 40

Time Course(min)

control

Acanthopanax

(8)

3)

.

, ,

.

“ ” ,

“

”

³⁾

.

1872 Mitchell

²³⁾

,

24)

.

,

3)

.

. , Bennett

Xie

²⁵⁾

(chronic con-

striction injury model; CCI) 4

chromic gut

. , Seltzer

²⁶⁾

(partial sciatic nerve ligation model;

PSL) , Kim Chung

²⁷⁾

5

6 (spinal nerve ligation model; SNL)

. DeLeo

²⁸⁾

,

.

29)

.

3 ,

,

2 ,

28

²⁹⁾

.

,

.

,

.

30-34)

. 1977 Dubuisson Dennis

³⁰⁾

,

(9)

phase , phase 1

5 , phase

2 15-20 .

, ,

30)

. Hunskaar

Hole

³⁵⁾

phase 1

, phase 2

.

. ,

Viana

³⁶⁾

Cymbopogon citratus phase 2

, Leal

³⁷⁾

coumarin

phase 2

. Abdel-Fattah

³⁸⁾

Nigella sativa oil

phase 1 , Nigella sativa

oil thymoquinone , ,

phase 1 phase 2

.

(Acanthopanax sessiliflorus)

39)

“

”

. syringin, eleuthe-

, , , ,

, , ,

, , , ,

40)

.

, , , ,

, , ,

(apoptosis) , (LPS)

, prostaglandin E2 ,

40,41)

.

42,43)

,

44)

,

FeSO4

⁴⁵⁾

,

46,47)

,

15)

.

. ,

10 , 30 , 60 , 120 88±5.4%,

100±0%, 94±2.7%, 80±8.9%

400mg/10ml/ 52±10.0%, 42±10.6%, 56

±8.2%, 48±8.8% 400mg/10ml/

(p<0.05) .

, 50mg/10ml/ 100mg/

10ml/ , 200mg/10ml/

, 400mg/10ml/

10

(10)

.

, 400mg/10ml/

.

(p>0.05) .

.

, 5 , 10

78.9±9.6 , 11.6±4.8 ,

100mg/10ml/kg 75.7±11.2

, 18.3±18.2 (p>0.05)

, 15 , 20 , 25

25.5±8.0 , 41.8±15.3 , 54.2±13.1

, 15.8±11.9 , 15.3±0.4 ,

37.6±8.4

(p<0.05) . phase 1

, phase 2

.

,

.

,

.

結論

. 1.

, 10 , 30 , 60 , 120 400mg/10ml/

. 2.

, .

3. , 15 , 20 , 25

.

參考文獻

1. . . : . 1995:1-32.

2. .

. ;1997.

3. , , .

. . 2001;1(1):

53-64.

4. . . :

. 1997;25-32.

5. , , , , ,

, , , , .

. . 2004;21

(3):145-167.

6. Shibata M, Ohkubo T, Takahashi H, Inoki R.

Modified formalin test: characteristic biphasic pain response. Pain. 1989;38(3):347-352.

7. , , , , ,

. , ,

c-fos

. . 2004;21(1):240-251.

(11)

9. .

. ;2003.

10. , , , , .

. . 2001;18(6):215-224.

11. .

. ;2003.

12. Dae Hyun Roh. Anti-nociceptive Effect of Bee Venom Stimulation on Neuropathic Pain using Sciatic Nerve Chronic Constriction Injury Model of Rats. Seoul National University;

2003.

13. , , , , ,

. Formalin-induced

Pain Behavior .

. 2000;17(2):139-152.

14. , , , , ,

. formalin

. .

2000;17(2):231-246.

15. , , . Human Monocyte

IL-8

. .

1995;10(1):49-58.

16. Yamazaki T, Shimosaka S, Sasaki H, Matsumura T, Tukiyama T, Tokiwa T. (+) -Syringaresinol-di-O-β-d-glucoside, a phenolic compound from Acanthopanax senticosus Harms, suppresses proinflammatory mediators in SW982 human synovial sarcoma cells by inhibiting activating protein-1 and/or nuclear factor-κB activities. Toxicology in Vitro, In Press, Corrected Proof, Available online 5 May 2007.

17. Jung HJ, Nam JH, Choi J, Lee KT, Park HJ.

Antiinflammatory effects of chiisanoside and chiisanogenin obtained from the leaves of

J Ethnopharmacol. 2005 Feb 28;97(2):359-67.

18. Tanelian and Cousins. Combined neurogenic and nociceptive pain in a patient with Pancoast tumor managed by epidural hydromorphone and oral carbamazepine. Pain. 1989 Jan; 36 (1):85-88.

19. Brose and Cousins. Subcutaneous lidocaine for treatment of neuropathic cancer pain. Pain.

1991;45:145-148.

20. Merskey H. Prepared by the IASP subcom- mittee on taxonomy. Classification of chronic pain : descriptions of chronic pain syndromes and definitions of pain terms. Pain. 1986;

3:S1-226.

21. Bonica JJ. In: Merskey H, Bogduk N eds.

Classification of chronic pain. 2nd ed. Seattle.

IASP Press. 1994;209-314.

22. Serra J. Overview of neuropathic pain syndromes. Acta Neurol Scand Suppl. 1999;173:

7-11.

23. Mitchell, S. W. Injuries of Nerves and Their Consequences. J. B. Lippincott. Philadelphia.

PA. 1872;252.

24. Wall, P. D., Devor, M., Inbal, R., Scadding, J. W., Schonfeld, D., Seltzer, Z. et al.

Autotomy following peripheral nerve lesions:

experimental anaesthesia dolorosa. Pain.

1979;7:103-113.

25. Bennett, G. J., Xie, Y. K. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain.

1988;33:87-107.

26. Seltzer, Z., Dubner, R., Shir, Y. A novel behavioral model of neuropathic pain disorders produced in rats by partial sciatic nerve injury.

Pain. 1990;43:205-218.

27. Kim, S. H., Chung, J. M. An experimental

(12)

model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain.

1992;50:355-363.

28. DeLeo, J. A., Coombs, D. W., Willenbring, S., Colburn, R. W., Fromm, C., Wagner, R. et al.

Characterization of a neuropathic pain model:

Sciatic cryoneurolysis in the rat. Pain. 1994;

56:9-16.

29. Lee, B.H. Won, R., Baik, E.J., Lee, S.H., &

Moon, C.H. An animal model of neuropathic pain employing injury to the sciatic nerve branches. NeuroReport, 2000;11(4):657-661.

30. Dubuisson D., Dennis SG. The formalin test:

a quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats. Pain. 1977;4: 161-174.

31. Abbott FV, Franklin KB, Ludwick RJ, Melzack R. Apparent lack of tolerance in the formalin test suggests different mechanisms for morphine analgesia in different types of pain. Pharmacol Biochem Behav. 1981;15:

637-640.

32. Abbott FV, Melzack R, Samuel C. Morphine analgesia in tail-flick and formalin pain tests is mediated by different neural systems. Exp Neurol. 1982;75:644-651.

33. Alreja V, Mutalik P, Nayar U, Manchanda SK.

The formalin test: a tonic pain model in the primate. Pain. 1984;20:97-104.

34. , , , , ,

. Formalin Test

. . 2004;21(2):223-233.

35. Hunskaar S., Hole K. The formalin test in mice: dissociation between inflammatory and non-inflammatory pain. Pain. 1987;30:103-114.

36. Viana GSB, Vale TG, Pinho RSN, Matos FJA.

Antinociceptive effect of the essential oil from Cymbopogon citratus in mice. J Ethnophar-

macol. 2000;70:323-327.

37. Leal LKAM, Ferreira AAG, Bezerra GA, Matos FJA, Viana GSB. Antinociceptive, anti-inflammatory and bronchodilator activities of Brazilian medicinal plants containing coumarin: a comparative study. J Ethnopharmacol.

2000;70:151-159.

38. Abdel-Fattah AM, Matsumoto K, Watanabe H. Antinociceptive effects of Nigella sativa oil and its major component, thymoquinone, in mice. Eur J Pharmacol. 2000;400:89-97.